Sangair

Patients with severe sepsis risk long hospital stays, amputations, organ failure, and in the worst cases, death. Many who survive sepsis experience long-term physical, cognitive, and psychological complications that can significantly impact their quality of life and at significant costs for society. Current treatments rely mainly on antibiotics, but today’s way of using antibiotics in general creates resistance, therefore is antibiotics efficiency not sufficient in all cases.

Sangair has developed SangAsept, a unique and patented technology that can complement today’s treatments. The method is based on a dialysis-like process where blood is treated outside the body for a short period, through a controlled gas mixture of oxygen and ozone. Preclinical results show that SangAsept effectively reduces bacteria commonly linked to sepsis while while modulating the immune response.